Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ruxolitinib |
| Synonyms | |
| Therapy Description |
Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov) |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ruxolitinib | Jakafi | INCB 18424|INCB018424|INCB18424 | JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15 | Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov) |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF3R N610H | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CSF3R N610H in culture (PMID: 30348809). | 30348809 |
| JAK3 L875H | hematologic cancer | predicted - sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L875H demonstrated some sensitivity to treatment with Jakafi (ruxolitinib) in culture, but were not as sensitive as cells expressing other JAK3 activating mutations (PMID: 31976485). | 31976485 |
| JAK2 V617F JAK2 L983F | Advanced Solid Tumor | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F and L983F demonstrated resistance to Jakafi (Ruxolitinib) treatment in cell culture and in a syngeneic mouse model (PMID: 26419724). | 26419724 |
| JAK2 R938Q | childhood B-cell acute lymphoblastic leukemia | resistant | Ruxolitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, bone marrow mononuclear cells from a pediatric B-cell acute lymphoblastic leukemia with an acquired Jak2 R938Q mutation were resistant to Jakafi (ruxolitinib) (PMID: 29025600). | 29025600 |
| JAK2 V617F | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915). | 39091915 |
| JAK2 rearrange | myeloid neoplasm | sensitive | Ruxolitinib | Guideline | Actionable | Jakafi (ruxolitinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a JAK2 rearrangement (NCCN.org). | detail... |
| JAK3 Y100A JAK3 L857P | Advanced Solid Tumor | decreased response | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793). | 26446793 |
| JAK2 V617F JAK2 L983F | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F and L983F was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 E985K | hematologic cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
| CSF3R T618I CSF3R Q741* | hematologic cancer | predicted - resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with Jakafi (ruxolitinib) in culture (PMID: 28031554). | 28031554 |
| JAK3 M511I | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 M511I were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
| JAK2 V617F JAK2 Y931C | cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). | 21393331 |
| JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
| JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F and Y931C was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 L902Q | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F and L902Q was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| FLT3 exon 14 ins JAK3 V722I | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I were resistant to treatment with Jakafi (ruxolitinib) in culture (PMID: 33149267). | 33149267 |
| JAK2 V617F JAK2 M929I | hematologic cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
| JAK2 L583_A586delinsS | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 L583_A586delinsS demonstrated resistance to inhibition of cell proliferation by Jakafi (ruxolitinib) in culture (PMID: 31697804). | 31697804 |
| JAK3 L857Q | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L857Q were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
| CSF3R T618I | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited colony formation in transformed bone marrow cells expressing CSF3R T618I in culture (PMID: 29572350). | 29572350 |
| CSF3R T618I | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited growth of a transformed cell line expressing CSF3R T618I in culture (PMID: 36579444). | 36579444 |
| CSF3R T618I CSF3R Q749* | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a clinical case study, Jakafi (ruxolitinib) treatment resulted in hematologic remission for at least 3 years in a patient with chronic neutrophilic leukemia harboring CSF3R T618I and Q749* along with DNMT3A R882C (PMID: 32577845). | 32577845 |
| JAK2 V617F JAK2 E1028K | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and E1028K in culture (PMID: 39091915). | 39091915 |
| JAK3 L857P | Advanced Solid Tumor | decreased response | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793). | 26446793 |
| JAK2 R683G JAK2 G935R | cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575). | 22271575 |
| JAK2 V617F JAK2 G935R | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575). | 22271575 |
| CSF3R T640N | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a Phase II trial, Jakafi (ruxolitinib) treatment resulted in an overall hematologic response rate of 35% (15/43, 4 complete and 11 partial responses) and a median overall survival of 18.8 months in patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia harboring CSF3R mutations T618I (n=20), T640N (n=1), and T615A (n=1), including a complete response in a CNL patient harboring CSF3R T640N (PMID: 31880950; NCT02092324). | 31880950 |
| CSF3R T618I | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a Phase II trial, Jakafi (ruxolitinib) treatment resulted in an overall hematologic response rate of 35% (15/43, 4 complete and 11 partial responses) and a median overall survival of 18.8 months in patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia harboring CSF3R mutations, including T618I (n=20), T640N (n=1), and T615A (n=1), with 2 complete and 9 partial responses in CNL patients harboring CSF3R T618I (PMID: 31880950; NCT02092324). | 31880950 |
| CSF3R T618I | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a clinical case study, Jakafi (ruxolitinib) treatment resulted in symptom improvement and decreased spleen and liver size lasting 5 months in a patient with chronic neutrophilic leukemia harboring CSF3R T618I along with SETBP1 G870S (PMID: 27068405). | 27068405 |
| CSF3R T618I CSF3R W791* | hematologic cancer | predicted - resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell survival (PMID: 28031554). | 28031554 |
| JAK2 V617F JAK2 I960V | hematologic cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
| JAK2 V617F JAK2 L902Q JAK2 R938E | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R938E was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 R938L | hematologic cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
| JAK2 V617F JAK2 L902Q JAK2 E1028K | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and E1028K was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F, L983F, and Q959H was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| CSF3R Q741* | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing CSF3R Q741* were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased total colony formation (PMID: 29977015). | 29977015 |
| CSF3R Q741* | hematologic cancer | predicted - sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing CSF3R Q741* were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell survival (PMID: 28031554). | 28031554 |
| JAK2 R867Q | hematologic cancer | decreased response | Ruxolitinib | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328). | 24398328 |
| CSF3R N579Y CSF3R Q739* CSF3R Q741* | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) treatment inhibited colony formation of hematopoietic progenitor cells isolated from the bone marrow of a patient with chronic neutrophilic leukemia harboring CSF3R N579Y, Q739*, and Q741* in culture (PMID: 36579444). | 36579444 |
| CSF3R W791* | hematologic cancer | predicted - sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing CSF3R W791* were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell survival (PMID: 28031554). | 28031554 |
| JAK2 Y931C | cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). | 21393331 |
| CSF3R T618I | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) reduced colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333, PMID: 29977015). | 26475333 29977015 |
| CSF3R W341C CSF3R W791* | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, (ruxolitinib) inhibited viability of a cell line expressing CSF3R W341C and W791* in culture (PMID: 28652245). | 28652245 |
| JAK3 V674A | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793). | 26446793 |
| CSF3R W341C | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited viability of a cell line expressing CSF3R W341C in culture (PMID: 28652245). | 28652245 |
| JAK2 V617F JAK2 R947Q | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915). | 39091915 |
| CSF3R N579Y | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) treatment inhibited colony formation and decreased viability of transformed cells expressing CSF3R N579Y in culture (PMID: 36579444). | 36579444 |
| FLT3 exon 14 ins JAK2 V617F | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and JAK2 V617F were resistant to treatment with Jakafi (ruxolitinib) in culture (PMID: 33149267). | 33149267 |
| JAK2 V617F JAK2 E987D | Advanced Solid Tumor | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F and E987D demonstrated resistance to Jakafi (Ruxolitinib) treatment in culture (PMID: 26419724). | 26419724 |
| JAK2 V617F JAK2 R971G | Advanced Solid Tumor | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F and R971G demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 26419724). | 26419724 |
| CSF3R N610S | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells exxpressing CSF3R N610S in culture (PMID: 30348809). | 30348809 |
| JAK2 V617F JAK2 Q959H | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and Q959H in culture (PMID: 39091915). | 39091915 |
| JAK3 Q988P | hematologic cancer | decreased response | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 Q988P were less sensitive to Jakafi (ruxolitinib) treatment compared to cells expressing JAK3 M511I in culture (PMID: 37712558). | 37712558 |
| JAK2 V617F JAK2 L902Q JAK2 R947Q | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R947Q was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| CSF3R T640N | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T640N in culture (PMID: 26475333). | 26475333 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03669965 | Phase II | Ruxolitinib KRT-232 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | Unknown status | USA | POL | HUN | FRA | ESP | DEU | 0 |
| NCT02092324 | Phase II | Ruxolitinib | Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia | Completed | USA | 0 |
| NCT02928978 | Phase II | Ruxolitinib | Ruxolitinib for Premalignant Breast Disease | Recruiting | USA | 0 |
| NCT02713386 | Phase Ib/II | Ruxolitinib Carboplatin + Paclitaxel | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT01712659 | Phase II | Ruxolitinib | Ruxolitinib for Adult T-Cell Leukemia | Terminated | USA | 0 |
| NCT03514069 | Phase I | Ruxolitinib Ruxolitinib + Temozolomide | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | Active, not recruiting | USA | 0 |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT04644211 | Phase II | Ruxolitinib | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Recruiting | USA | 0 |
| NCT04807777 | Phase II | Ruxolitinib | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT02420717 | Phase II | Ruxolitinib Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Dasatinib Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
| NCT02117479 | Phase III | Ruxolitinib Capecitabine | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Terminated | USA | NZL | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 3 |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
| NCT02966353 | Phase II | Ruxolitinib | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) | Completed | TUR | ITA | GRC | ESP | DEU | CAN | BGR | BEL | AUT | 2 |
| NCT03123588 | Phase II | Ruxolitinib Anagrelide | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | Terminated | USA | 0 |
| NCT02015208 | Phase Ib/II | Ruxolitinib | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | Completed | CAN | 0 |
| NCT02251821 | Phase II | Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide | JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Active, not recruiting | USA | 0 |
| NCT04603495 | Phase III | CPI-0610 + Ruxolitinib Ruxolitinib | Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 5 |
| NCT02119676 | Phase II | Regorafenib Ruxolitinib | Study of Ruxolitinib in Colorectal Cancer Patients | Terminated | USA | ISR | GBR | FRA | ESP | DEU | AUS | 1 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
| NCT02038036 | Phase III | Peginterferon alfa-2b Anagrelide Hydroxyurea Pipobroman Ruxolitinib | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2) | Completed | TUR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
| NCT01895842 | Phase I | Ruxolitinib | Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
| NCT03571321 | Phase I | Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Sulfate Rituximab Doxorubicin | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
| NCT02723994 | Phase II | Prednisone Dexamethasone + Doxorubicin Leucovorin Mercaptopurine + Thioguanine Asparaginase + Cytarabine Ruxolitinib Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Sulfate | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | Active, not recruiting | USA | CAN | 1 |
| NCT03722407 | Phase II | Ruxolitinib | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | Active, not recruiting | USA | 0 |
| NCT02974647 | Phase II | Ruxolitinib | Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | Recruiting | USA | 0 |
| NCT01164163 | Phase I | Ruxolitinib | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | Completed | USA | 0 |
| NCT04551053 | Phase III | Parsaclisib + Ruxolitinib Ruxolitinib | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | Terminated | USA | TUR | ROU | POL | NOR | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DEU | BEL | AUT | 4 |
| NCT04551066 | Phase III | Ruxolitinib Parsaclisib + Ruxolitinib | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | Active, not recruiting | USA | TUR | POL | NOR | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | BEL | AUT | 3 |
| NCT01822756 | Phase I | Ruxolitinib | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT03153982 | Phase II | Ruxolitinib | Ruxolitinib in Operable Head and Neck Cancer | Terminated | USA | 0 |
| NCT02955940 | Phase II | Ruxolitinib Capecitabine + Regorafenib Capecitabine + Regorafenib + Ruxolitinib | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Active, not recruiting | USA | POL | 0 |
| NCT05592015 | Phase II | Ruxolitinib | Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | Recruiting | USA | 0 |
| NCT03041636 | Phase II | Ruxolitinib | Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
| NCT03801434 | Phase II | Ruxolitinib | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Recruiting | USA | 0 |
| NCT04116502 | Phase III | Ruxolitinib Hydroxyurea Alpha 2 Interferon | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE) | Recruiting | GBR | 0 |
| NCT01776723 | Phase II | Ruxolitinib | A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib | Completed | USA | 0 |
| NCT01562873 | Phase II | Ruxolitinib | Ruxolitinib in Patients With Breast Cancer | Terminated | USA | 0 |
| NCT01751425 | Phase II | Ruxolitinib | Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) | Terminated | USA | 0 |
| NCT01431209 | Phase II | Ruxolitinib | Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
| NCT04562389 | Phase III | Ruxolitinib + Selinexor Ruxolitinib | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BGR | BEL | 3 |
| NCT03117751 | Phase II | Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Active, not recruiting | USA | AUS | 0 |
| NCT02131584 | Phase II | Ruxolitinib | Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
| NCT03286530 | Phase II | Ruxolitinib | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | Recruiting | USA | 0 |
| NCT03165734 | Phase II | Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide | A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) | Recruiting | USA | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BGR | AUS | 8 |
| NCT02386800 | FDA approved | Ruxolitinib Panobinostat + Ruxolitinib | CINC424A2X01B Rollover Protocol | Active, not recruiting | TUR | SWE | POL | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BGR | BEL | AUS | 8 |
| NCT04472598 | Phase III | Ruxolitinib Navitoclax + Ruxolitinib | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1) | Active, not recruiting | USA | TUR | SWE | NZL | NLD | ITA | ISR | HRV | GRC | GBR | FRA | ESP | DEU | CAN | BGR | BEL | AUT | AUS | 7 |
CKB BOOST